12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BIT225: Interim Phase II data

Interim data from 12 treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all 6 patients with HCV genotype 3 infection who received twice-daily BIT225 plus peginterferon alfa-2b and ribavirin for 28 days achieved undetectable HCV RNA levels at week 12. Biotron said that...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >